Lessons Learned from Trial Replication Analyses: Findings from the DUPLICATE Demonstration Project

Virtual Public Webinar
May 10, 2022 | 12:00 pm – 2:30 pm ET

Agenda

On May 10, 2022, the Duke-Margolis Center for Health Policy will convene a public workshop, under a cooperative agreement with the U.S. Food and Drug Administration, to review findings from the RCT-DUPLICATE Demonstration Project. The discussion will build on a previous public workshop convened by Duke-Margolis on February 16, 2021, which shared preliminary results from trial replication efforts with the goal of better understanding the strengths and limitations of observational studies. The current workshop will report on additional results and further elaborate on lessons learned from RCT-DUPLICATE; potential implications for regulatory decision-making will also be explored.

12:00 pm Welcome and Introductions

Rachele Hendricks-Sturrup, Duke-Margolis Center for Health Policy

12:05 pm Opening Remarks

John Concato, U.S. Food and Drug Administration

12:15 pm Overview of Technical Findings: The RCT-DUPLICATE Demonstration Project

Objectives: The results of the completed RCT-DUPLICATE demonstration project, including 32 trial emulations, will be presented. Presenters will briefly review the scientific methodology and focus on presenting results with important insights regarding key findings beyond the replication studies presented at the February 2021 workshop.

Moderator: Rachele Hendricks-Sturrup, Duke-Margolis Center for Health Policy

Presenters:
- Shirley Wang, Brigham and Women’s Hospital
- Sebastian Schneeweiss, Brigham and Women’s Hospital

1:15 pm Break
1:20 pm  **Stakeholder Reactions to Result Findings, and Implications**

*Objective:* Panelists will comment on the presented results and offer lessons learned from the demonstration project. The panel will also consider the implications of these results for potential use in regulatory decision-making.

*Moderator:* **Rachele Hendricks-Sturrup**, Duke-Margolis Center for Health Policy

*Panelists:*
- **Ken Quinto**, FDA, CDER
- **Melvin Olson**, Novartis
- **Issa Dahabreh**, Harvard T.H. Chan School of Public Health
- **Steven Goodman**, Stanford University
- **Shirley Wang**, Brigham and Women’s Hospital
- **Sebastian Schneeweiss**, Brigham and Women’s Hospital

2:25 pm  **Concluding Remarks**

**Rachele Hendricks-Sturrup**, Duke-Margolis Center for Health Policy

2:30 pm  **Adjournment**

---

_Funding for this workshop was made possible in part by a cooperative agreement from the U.S. Food and Drug Administration Center for Drug Evaluation and Research. The views expressed in written workshop materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsements by the U.S. Government._